Ihsan Nijem

776 total citations
24 papers, 639 citations indexed

About

Ihsan Nijem is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Ihsan Nijem has authored 24 papers receiving a total of 639 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Radiology, Nuclear Medicine and Imaging, 14 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Ihsan Nijem's work include Monoclonal and Polyclonal Antibodies Research (16 papers), HER2/EGFR in Cancer Research (11 papers) and Liver physiology and pathology (7 papers). Ihsan Nijem is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (16 papers), HER2/EGFR in Cancer Research (11 papers) and Liver physiology and pathology (7 papers). Ihsan Nijem collaborates with scholars based in United States, Switzerland and Japan. Ihsan Nijem's co-authors include Amita Joshi, Xiangdan Wang, Pin Yee Wong, David E. Allison, Devin B. Tesar, Ryan Hutchinson, Zhenling Yao, Reed J. Harris, Alavattam Sreedhara and Jihong Yang and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Ihsan Nijem

24 papers receiving 599 citations

Peers

Countries citing papers authored by Ihsan Nijem

Since Specialization

Citations

This map shows the geographic impact of Ihsan Nijem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ihsan Nijem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ihsan Nijem more than expected).

Fields of papers citing papers by Ihsan Nijem

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ihsan Nijem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ihsan Nijem. The network helps show where Ihsan Nijem may publish in the future.

Co-authorship network of co-authors of Ihsan Nijem

This figure shows the co-authorship network connecting the top 25 collaborators of Ihsan Nijem. A scholar is included among the top collaborators of Ihsan Nijem based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ihsan Nijem. Ihsan Nijem is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cross validation of pharmacokinetic bioanalytical methods: Experimental and statistical design 2024 ·Journal of Pharmaceutical and Biomedical Analysis ·Ihsan Nijem, R. L. Elliott, Jochen Brumm, Luna Liu, Keyang Xu, (unknown), Robert L. Hendricks, Bing Wang, Patricia Siguenza	2
2	Implementation of a Three-Way Comparability Assessment for a Bioanalytical Anti-Drug Antibody Method 2024 ·The AAPS Journal ·(unknown), Ihsan Nijem, (unknown), Robert L. Hendricks	1
3	Bioanalytical Method Comparison Strategy for Clinical Anti-drug Antibody Immunoassays 2024 ·The AAPS Journal ·(unknown), (unknown), (unknown), Wei Yan, Ihsan Nijem, Patricia Siguenza, Yang Song	2
4	Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study 2019 ·Cancer Chemotherapy and Pharmacology ·Whitney P. Kirschbrown, Matts Kågedal, Bei Wang, Lars Lindbom, Adam Knott, (unknown), Sharareh Monemi, Ihsan Nijem, Sandhya Girish, (unknown), Debora Fumagalli, Robin McConnell, Guy Jérusalem, Chris Twelves, José Baselga, Gϋnter von Minckwitz, José Bines, Amit Garg	9
5	Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer 2019 ·Cancer Chemotherapy and Pharmacology ·Whitney P. Kirschbrown, Bei Wang, Ihsan Nijem, Atsushi Ohtsu, Paulo M. Hoff, Manish A. Shah, Lin Shen, Yoon‐Koo Kang, María Alsina, Sandhya Girish, Amit Garg	9
6	Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study 2018 ·The Journal of Clinical Pharmacology ·Whitney P. Kirschbrown, Chris Wynne, Matts Kågedal, (unknown), Hanbin Li, Bei Wang, Ihsan Nijem, Tanja Badovinac Črnjević, (unknown), Sarah Heeson, Jennifer Eng‐Wong, Amit Garg	28
7	Pharmacokinetic (PK) and exposure-response (ER) analysis of pertuzumab (P) in patients (pts) with HER2-positive metastatic gastroesophageal junction and gastric cancer (mGEJC/GC). 2018 ·Journal of Clinical Oncology ·Whitney P. Kirschbrown, Bei Wang, Ihsan Nijem, Atsushi Ohtsu, Paulo M. Hoff, Manish A. Shah, Lin Shen, Yoon‐Koo Kang, Josep Tabernero, Sandhya Girish, Amit Garg	1
8	Placental and Fetal Effects of Onartuzumab, a Met/HGF Signaling Antagonist, When Administered to Pregnant Cynomolgus Monkeys 2018 ·Toxicological Sciences ·Rodney A. Prell, Noël Dybdal, (unknown), (unknown), Ihsan Nijem, Wendy Halpern	6
9	Optimizing Hybrid LC–MS/MS Binding Conditions is Critical: Impact of Biotransformation on Quantification of Trastuzumab 2018 ·Bioanalysis ·Luna Liu, Keyang Xu, (unknown), Mauricio Maia, Mary Mathieu, (unknown), Jihong Yang, Ihsan Nijem, Surinder Kaur	16
10	Pharmacokinetic and exposure–response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer 2017 ·Cancer Chemotherapy and Pharmacology ·Angelica Quartino, Hanbin Li, Jin Y. Jin, Daisuke Wada, Mark Benyunes, Virginia McNally, Lucia Viganò, Ihsan Nijem, Bert L. Lum, Amit Garg	17
11	A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function 2016 ·Clinical Pharmacokinetics ·Chunze Li, Priya Agarwal, Ekaterina Gibiansky, Jin Y. Jin, Susan Dent, Anthony Gonçalvès, Ihsan Nijem, Alexander Strasak, (unknown), (unknown), (unknown), Sandhya Girish	11
12	Ethnic sensitivity assessment of the antibody–drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer 2016 ·Cancer Chemotherapy and Pharmacology ·Chunze Li, Bei Wang, Dan Lu, Jin Y. Jin, Yuying Gao, (unknown), (unknown), Ihsan Nijem, Michael W. Lu, Alexander Strasak, (unknown), Sandhya Girish	14
13	Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies 2014 ·Clinical Cancer Research ·Ravi Salgia, Premal H. Patel, John Bothos, Wei Yu, Steve Eppler, Priti S. Hegde, Shuang Bai, Surinder Kaur, Ihsan Nijem, Daniel V.T. Catenacci, Amy Peterson, Mark J. Ratain, Blasé N. Polite, Janice M. Mehnert, Rebecca A. Moss	56
14	Nonclinical Evaluation of the Serum Pharmacodynamic Biomarkers HGF and Shed MET following Dosing with the Anti-MET Monovalent Monoclonal Antibody Onartuzumab 2013 ·Molecular Cancer Therapeutics ·Elaine Mai, Zhong Zheng, Youjun Chen, Jing Peng, Christophe Severin, Ellen Filvaroff, Mally Romero, William Mallet, Surinder Kaur, Thomas Gelzleichter, Ihsan Nijem, Mark Merchant, Judy Young	10
15	Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentration–Effect Data to Support Clinical Development 2013 ·Clinical Cancer Research ·Hong Xiang, Brendan C. Bender, Arthur E. Reyes, Mark Merchant, Nelson L. ‘Shasha’ Jumbe, Mally Romero, (unknown), Ihsan Nijem, Elaine Mai, Judy Young, Amy Peterson, Lisa A. Damico‐Beyer	28
16	Absence of pharmacokinetic drug–drug interaction of pertuzumab with trastuzumab and docetaxel 2013 ·Anti-Cancer Drugs ·Javier Cortés, Sandra M. Swain, Iveta Kudaba, Maik Hauschild, Taral Patel, (unknown), Norikazu Masuda, Virginia McNally, Graham Ross, Mike Brewster, Jean‐Francois Marier, (unknown), Amit Garg, Ihsan Nijem, Jennifer Visich, Bert L. Lum, José Baselga	19
17	Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors 2013 ·The Journal of Clinical Pharmacology ·Xin Yan, (unknown), Stephen Eppler, Lisa A. Damico‐Beyer, Amita Joshi, John D. Davis, Surinder Kaur, Ihsan Nijem, John Bothos, Amy Peterson, Premal H. Patel, Shuang Bai	33
18	Human pharmacokinetic (PK) characterization of the novel dual-action anti-HER3/EGFR antibody MEHD7945A (MEHD) in patients with refractory/recurrent epithelial tumors. 2012 ·Journal of Clinical Oncology ·Manuel Hidalgo, Antonio Calles, Dejan Juric, Rodrigo Dienstmann, (unknown), Wells A. Messersmith, George R. Blumenschein, José Baselga, Josep Tabernero, Andrés Cervantes, Antonio Jimeno, (unknown), Shuang Bai, Pavel Gurevich, Ihsan Nijem, Scott N. Holden, John D. Davis, Wendy Halpern, Andrea Pirzkall, Xin Yan	1
19	Abstract 4717: Final results from the Phase I study of MetMAb, a monovalent antagonist antibody to the receptor Met, dosed as single agent and in combination with bevacizumab in patients with advanced solid malignancies 2011 ·Cancer Research ·Rebecca A. Moss, John Bothos, Premal H. Patel, Amy Peterson, Steve Eppler, Shuang Bai, Ihsan Nijem, Luc Desnoyers, Surinder Kaur, Jiping Zha, Wei Yu, Joe Leigh Simpson, Mark J. Ratain, Antoinette R. Tan, Mark N. Stein, Janice M. Mehnert, Ravi Salgia	8
20	Charge variants in IgG1 2010 ·mAbs ·Leslie A. Khawli, (unknown), Ryan Hutchinson, (unknown), Jihong Yang, Xiangdan Wang, Zhenling Yao, Alavattam Sreedhara, Tony Cano, Devin B. Tesar, Ihsan Nijem, David E. Allison, Pin Yee Wong, Yung‐Hsiang Kao, Cynthia Quan, Amita Joshi, Reed J. Harris, Paul A. Motchnik	340

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact